EIK1003-001 (IMP1734-101) EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tum

NCT06253130

EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors

Principal Investigator

Guru Sonpavde

Sponsor

Eikon/IMPACT Therapeutics

The study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in the future. The study treatment has not yet been approved for treatment of cancers by the regulatory authorities in any country. This is a first-in-human study, which means that this is the first time that the study drug will be given to humans.

This study is currently enrolling.